Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 723Neoplasms 461Prostatic Neoplasms 398Carcinoma, Non-Small-Cell Lung 388Lung Neoplasms 311Leukemia, Myeloid, Acute 301Multiple Myeloma 270Colorectal Neoplasms 243Neoplasm Metastasis 240Pancreatic Neoplasms 238Leukemia 235Melanoma 217Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 195Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 174Myelodysplastic Syndromes 168Leukemia, Lymphocytic, Chronic, B-Cell 168Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 116Squamous Cell Carcinoma of Head and Neck 109

Interventions

ibrutinib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × Hypergammaglobulinemia × Clear all
NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia

Weill Medical College of Cornell University

Phase 2 Terminated
1 enrolled 8 charts
Lymphoid

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡